Related Experiment Videos
Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients
K H Mak1, M B Effron, D J Moliterno
1Department of Cardiology at the National Heart Centre, Tan Tock Seng Hospital, Singapore.
Insights
Glycoprotein (GP) IIb/IIIa antagonists effectively reduce major adverse cardiovascular events in elderly patients undergoing percutaneous coronary interventions or treated for acute coronary syndromes. These antiplatelet agents offer significant benefits without increasing bleeding risk.
Area of Science:
- Cardiology
- Pharmacology
- Geriatrics
Background:
- Cardiovascular diseases, particularly coronary artery disease, represent a significant global health challenge, especially in aging populations.
- Platelets play a critical role in the pathophysiology of atherothrombotic events.
- The glycoprotein (GP) IIb/IIIa receptor is a key target for antiplatelet therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of GP IIb/IIIa antagonists in elderly patients.
- To assess the impact of these agents on ischemic complications in specific cardiovascular scenarios.
Main Methods:
- Pooled analysis of large-scale clinical trials involving patients undergoing percutaneous coronary interventions (PCI) and those with acute coronary syndromes (ACS).
- Specific focus on patient subgroups aged over 70 years.
- Comparison of outcomes between GP IIb/IIIa antagonist treatment and placebo or standard care.
Main Results:
- In elderly patients (>70 years) undergoing PCI, abciximab reduced the composite endpoint of death or myocardial infarction by 30 days from 10.0% to 5.9% (OR 0.56; 95% CI, 0.37 to 0.83) compared to placebo.
- This benefit was observed without a significant increase in major bleeding complications.
- Similar positive trends were noted for tirofiban and eptifibatide in elderly patients with ACS.
Conclusions:
- GP IIb/IIIa antagonists are effective in preventing ischemic complications in elderly patients.
- These agents can be safely administered to the elderly population for PCI and ACS treatment.
- The findings support the use of GP IIb/IIIa antagonists as a valuable therapeutic option for older adults at high cardiovascular risk.
Abstract:
With increasing age of the general population, cardiovascular diseases are becoming a greater health burden. Coronary artery disease remains a major cause of morbidity and mortality worldwide. Among the various pathophysiological processes, platelets play a pre-eminent role. With the identification of the glycoprotein (GP) IIb/IIIa receptor as the final common pathway for platelet aggregation, potent antiplatelet agents have been developed. These GP IIb/IIIa antagonists have been shown to be effective in improving outcomes among patients undergoing percutaneous coronary interventions and for the treatment of acute coronary syndromes. By pooling the results of several large-scale trials, these benefits have been found to extend to the elderly population. Among 7860 patients undergoing percutaneous coronary intervention, the occurrence of death or myocardial infarction at 30 days was reduced from 10.0 to 5.9% (odds ratio 0.56; 95% confidence level, 0.37 to 0.83) with abciximab compared with placebo, in those >70 years of age. Importantly, this benefit was achieved without an increase in major bleeding complications. Similarly favourable trends were also observed among elderly patients treated with tirofiban or eptifibatide for acute coronary syndromes. As such, GP IIb/IIIa antagonists are effective in preventing ischaemic complications and can be safely administered to elderly patients.